ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Safety and Efficacy of an Anti-Psychotic in Patients With Schizophrenia

This study has been completed.

Sponsored by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Information provided by: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
ClinicalTrials.gov Identifier: NCT00074477
  Purpose

The purpose of this study is to determine the efficacy (how well the drug works), safety, and side effects of paliperidone palmitate injection compared to placebo in the treatment of the symptoms of schizophrenia in adults. The placebo used in this study was a nutritional substance known as 20% Intralipid emulsion given to patients requiring intravenous feedings.


Condition Intervention Phase
Schizophrenia
Drug: R092670
Phase II

MedlinePlus related topics:   Schizophrenia   

Drug Information available for:   Paliperidone    Paliperidone Palmitate   

U.S. FDA Resources

Study Type:   Interventional
Study Design:   Treatment, Randomized, Double-Blind, Parallel Assignment, Safety/Efficacy Study
Official Title:   A Randomized, Double-Blind, Placebo-Contolled Study to Evaluate the Efficacy and Safety of 50 and 100 mg-eq of Paliperidone Palmitate in Patients With Schizophrenia

Further study details as provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:

Primary Outcome Measures:
  • The change in total PANSS score from the start of the double-blind treatment period to the end of the double-blind treatment period.

Secondary Outcome Measures:
  • Changes from the start of to the end of the double-blind treatment period in CGI-S and in the PANSS subscales for specific symptoms. Incidence of adverse events, labs and ECGs throughout study.

Estimated Enrollment:   210
Study Start Date:   October 2003
Study Completion Date:   July 2004

Detailed Description:

Paliperidone palmitate is an aqueous suspension that releases paliperidone gradually over a period of about 1 month and is under development to provide a sustained and stable level of paliperidone. This is a randomized (patients will be assigned to different treatment groups based solely on chance), double-blind (neither the patient nor the physician will know if placebo or drug is being given and at what dose), placebo-controlled, multicenter study in patients with schizophrenia. The study consists of a screening period (maximum 5 days, including a 3-day washout of psychotropic medications other than antidepressants, if applicable); a 7-day, open-label, oral run-in period; and a 64-day double-blind treatment period. The total duration of the study is approximately 11 weeks. Efficacy will be evaluated during the study using the Positive and Negative Symptom Scale for Schizophrenia (PANSS) and the Clinical Global Impression - Severity (CGI-S) scale. Safety will be evaluated by monitoring adverse events and changes in clinical laboratory results, including prolactin levels; physical examination results; tardive dyskinesia will be rated using the Abnormal Involuntary Movement Scale (AIMS), akathisia will be rated according to the Barnes Akathisia Rating Scale (BARS), extrapyramidal symptoms will be evaluated using the Simpson-Angus Rating Scale (SAS); electrocardiogram (ECG); vital sign measurements; and concomitant therapy.

ER OROS paliperidone (6 or 12 mg) or IR paliperidone (2 or 4 mg) oral dosage administered daily for 7 days (Day -7 to -1), followed by i.m. injections of paliperidone palmitate (either 50 mg eq. or 100 mg eq.), or placebo on Days 1, 8, and 36 of the study.

  Eligibility
Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Criteria

Inclusion Criteria:

  • Patients diagnosed with schizophrenia
  • For at least 1 year before screening
  • Meet PANSS score criteria
  • Must agree to hospitalization for a minimum of 14 days
  • Body mass index (BMI) <35.0 kilogram (kg)/meter (m)2

Exclusion Criteria:

  • Patients who are involuntarily committed as in-patients
  • Have a DSM-IV Axis I diagnosis other than schizophrenia
  • Have a DSM-IV diagnosis of substance dependence within 3 months before screening (nicotine, caffeine dependence, and history of recreational use of marijuana are not exclusionary)
  • Have a decrease of >/=25% in the PANSS score between screening and predose
  • Previous lack of response to 2 adequate trials of antipsychotic treatment
  • Have a significant risk of suicidal, homicidal, or violent ideation or behavior
  • Have severe gatrointestinal narrowing (pathologic or iatrogenic)
  • Current presence of any significant or unstable medication condition
  • Treatment with any protocol disallowed therapies
  • Clinically significant result from screening laboratory or ECG
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00074477

Sponsors and Collaborators
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Investigators
Study Director:     Johnson & Johnson Pharmaceutical Research and Development, L.L.C. Clinical Trial     Johnson & Johnson Pharmaceutical Research & Development, L.L.C.    
  More Information


Study ID Numbers:   CR004357
First Received:   December 12, 2003
Last Updated:   February 28, 2008
ClinicalTrials.gov Identifier:   NCT00074477
Health Authority:   United States: Food and Drug Administration

Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:
R092670  
Paliperidone palmitate  
Schizophrenia  
antipsychotic  

Study placed in the following topic categories:
Schizophrenia
Mental Disorders
9-hydroxy-risperidone
Psychotic Disorders
Schizophrenia and Disorders with Psychotic Features

ClinicalTrials.gov processed this record on November 19, 2008




Links to all studies - primarily for crawlers